|
1
|
Meyers PA, Schwartz CL, Krailo M,
Kleinerman ES, Betcher D, Bernstein ML, et al: Osteosarcoma: a
randomized, prospective trial of the addition of ifosfamide and/or
muramyl tripeptide to cisplatin, doxorubicin, and high-dose
methotrexate. J Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bacci G, Forni C, Longhi A, Ferrari S,
Mercuri M, Bertoni F, et al: Local recurrence and local control of
non-metastatic osteosarcoma of the extremities: A 27-year
experience in a single institution. J Surg Oncol. 96:118–123.
2007.PubMed/NCBI
|
|
3
|
Jawad MU, Cheung MC, Clarke J, Koniaris LG
and Scully SP: Osteosarcoma: Improvement in survival limited to
high-grade patients only. J Cancer Res Clin Oncol. 137:597–607.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mialou V, Philip T, Kalifa C, Perol D,
Gentet JC, Marec-Berard P, et al: Metastatic osteosarcoma at
diagnosis: Prognostic factors and long-term outcome the French
pediatric experience. Cancer. 104:1100–1109. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hegyi M, Semsei AF, Jakab Z, Antal I, Kiss
J, Szendroi M, et al: Good prognosis of localized osteosarcoma in
young patients treated with limb-salvage surgery and chemotherapy.
Pediatr Blood Cancer. 57:415–422. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang L and Zhang S: ZM447439, the Aurora
kinase B inhibitor, suppresses the growth of cervical cancer SiHa
cells and enhances the chemosensitivity to cisplatin. J Obstet
Gynaecol Res. 37:591–600. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang WR, Yang SS, Lin JX, Zeng ZY, Liu DM
and Liu HT: Expression of Aurora-B in non-small cell lung cancer
and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao.
29:1853–1856. 2009.(In Chinese).
|
|
8
|
Qi G, Ogawa I, Kudo Y, Miyauchi M,
Siriwardena BS, Shimamoto F, et al: Aurora-B expression and its
correlation with cell proliferation and metastasis in oral cancer.
Virchows Arch. 450:297–302. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Abdullah AS, Foong C and Murata-Hori M:
Specific distribution of overexpressed Aurora-B kinase during
interphase of normal epithelial cells. Cancer Cell Int. 5:312005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Zhou W, Wei L, Jin J, Tang K, Li C,
et al: The effect of Aurora kinases on cell proliferation, cell
cycle regulation and metastasis in renal cell carcinoma. Int J
Oncol. 41:2139–2149. 2012.PubMed/NCBI
|
|
11
|
Tuncel H, Shimamoto F, Kaneko Guangying Qi
H, Aoki E, Jikihara H, et al: Nuclear Aurora-B and cytoplasmic
Survivin expression is involved in lymph node metastasis of
colorectal cancer. Oncol Lett. 3:1109–1114. 2012.PubMed/NCBI
|
|
12
|
Pohl A, Azuma M, Zhang W, Yang D, Ning Y,
Winder T, et al: Pharmacogenetic profiling of Aurora kinase B is
associated with overall survival in metastatic colorectal cancer.
Pharmacogenomics J. 11:93–99. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gully CP, Zhang F, Chen J, Yeung JA,
Velazquez-Torres G, Wang E, et al: Antineoplastic effects of an
Aurora-B kinase inhibitor in breast cancer. Mol Cancer. 9:422010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen YJ, Chen CM, Twu NF, Yen MS, Lai CR,
Wu HH, et al: Overexpression of Aurora-B is associated with poor
prognosis in epithelial ovarian cancer patients. Virchows Arch.
455:431–440. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Evans RP, Naber C, Steffler T, Checkland
T, Maxwell CA, Keats JJ, et al: The selective Aurora-B kinase
inhibitor AZD1152 is a potential new treatment for multiple
myeloma. Br J Haematol. 140:295–302. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Adams RR, Eckley DM, Vagnarelli P,
Wheatley SP, Gerloff DL, Mackay AM, et al: Human INCENP colocalizes
with the Aurora-B/AIRK2 kinase on chromosomes and is overexpressed
in tumour cells. Chromosoma. 10:65–74. 2011.PubMed/NCBI
|
|
17
|
Yoon MJ, Park SS, Kang YJ, Kim IY, Lee JA,
Lee JS, et al: Aurora B confers cancer cell resistance to
TRAIL-induced apoptosis via phosphorylation of survivin.
Carcinogenesis. 33:492–500. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hartsink-Segers SA, Zwaan CM, Exalto C,
Luijendijk MW, Calvert VS, Petricoin EF, et al: Aurora kinases in
childhood acute leukemia: the promise of Aurora-B as therapeutic
target. Leukemia. 27:560–568. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie F, Lang Q, Zhou M, Zhang H, Zhang Z,
Zhang Y, et al: The dietary flavonoid luteolin inhibits Aurora-B
kinase activity and blocks proliferation of cancer cells. Eur J
Pharm Sci. 46:388–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li J, Hu H, Lang Q, Zhang H, Huang Q, Wu Y
and Yu L: A thienopyrimidine derivative induces growth inhibition
and apoptosis in human cancer cell lines via inhibitingAurora-B
kinase activity. Eur J Med Chem. 65:151–157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamauchi T, Uzui K, Shigemi H, Negoro E,
Yoshida A and Ueda T: Aurora-B inhibitor barasertib and cytarabine
exert a greater-than-additive cytotoxicity in acute myeloid
leukemia cells. Cancer Sci. 104:926–933. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li J, Lang Q, Zhang H, Huang Q and Yu L:
S39, a novel Aurora B kinase inhibitor, shows potent antineoplastic
activity in human Hela cervical cancer cell line. Biotechnol Lett.
35:853–860. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie H, Lee MH, Zhu F, Reddy K, Peng C, Li
Y, Lim do Y, et al: Identification of an Aurora kinase inhibitor
specific for the Aurora-B isoform. Cancer Res. 73:716–724. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wilkinson RW, Odedra R, Heaton SP, Wedge
SR, Keen NJ, Crafter C, et al: AZD1152, a selective inhibitor of
Aurora-B kinase, inhibits human tumor xenograft growth by inducing
apoptosis. Clin Cancer Res. 13:3682–3688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang J, Ikezoe T, Nishioka C, Tasaka T,
Taniguchi A, Kuwayama Y, et al: AZD1152, a novel and selective
Aurora-B kinase inhibitor, induces growth arrest, apoptosis, and
sensitization for tubulin depolymerizing agent or topoisomerase II
inhibitor in human acute leukemia cells in vitro and in vivo.
Blood. 110:2034–2040. 2007. View Article : Google Scholar
|
|
26
|
Azzariti A, Bocci G, Porcelli L,
Fioravanti A, Sini P, Simone GM, et al: Aurora-B kinase inhibitor
AZD1152: determinants of action and ability to enhance
chemotherapeutics effectiveness in pancreatic and colon cancer. Br
J Cancer. 104:769–780. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bonet C, Giuliano S, Ohanna M, Bille K,
Allegra M, Lacour JP, et al: Aurora-B is regulated by the
mitogen-activated protein kinase/extracellular signal-regulated
kinase (MAPK/ERK) signaling pathway and is a valuable potential
target in melanoma cells. J Biol Chem. 287:29887–29998. 2012.
View Article : Google Scholar
|
|
28
|
Takeshita M, Koga T, Takayama K, Ijichi K,
Yano T, Maehara Y, et al: Aurora-B overexpression is correlated
with aneuploidy and poor prognosis in non-small cell lung cancer.
Lung Cancer. 80:85–90. 2013. View Article : Google Scholar : PubMed/NCBI
|
